Hepatitis B virus reinfection after liver transplantation: Related risk factors and perspective

Hepatobiliary and Pancreatic Diseases International

Volumn 4, Issue 4, 2005, Pages 502-508

  Wu, Li Ming ^a   Xu, Xiao ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatitis B virus reinfection; Liver transplantation; Related risk factors

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ADEFOVIR; ANTIVIRUS AGENT; CD20 ANTIBODY; CD40 ANTIGEN; CYCLOSPORIN A; FAMCICLOVIR; FINGOLIMOD; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAMIVUDINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; VIRUS DNA;

BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; ETHNIC DIFFERENCE; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HLA MATCHING; HUMAN; IMMUNOMODULATION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; ORGAN DONOR; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; PROGNOSIS; REINFECTION; REVIEW; RISK FACTOR; SURVIVAL TIME; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE THERAPY; HEPATITIS B; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS;

EID: 28444472813     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. World Health Organization: The World Health Report. World Health Organization, Geneva, Switzerland. 1997.
2. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000) WHO Web site. 2000. http://who.int/inf-fs/en/fact204.html.
3. Wu J, Zheng SS. Liver transplantation in China: problems and their solutions. Hepatobiliary Pancreat Dis Int 2004;3:170-174.
4. Zheng SS, Liang TB, Xu X. 10-year review of 120 cases of liver transplantation. Chin J Gen Surg 2003;18:71-73.
5. Karliova M, Malago M, Trippler M, Valentin-Gamazo C, Rothaar T, Broelsch CE, et al. Seroconversion in patients with acute hepatitis B reinfection after liver transplantation with a combined treatment of lamivudine and hepatitis hepatitis B immune globulin. Transplant Proc 2002;34:3319-3322.
6. Yue Y, Meng J, Zhang S. Mechanism of peripheral blood mononuclear cell invasion by HBV on artificial immunization in newborns. Chin Med J (Engl) 2002;115:1380-1382.
7. Seehofer D, Rayes N, Steinmuller T, Muller AR, Settmacher U, Neuhaus R, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001;7:976-982.
8. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611-620.
9. Lu SC, Yan LN, Li B, Ma YK, Liu C, Wen TF, et al. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report. Hepatobiliary Pancreat Dis Int 2003;2:196-201.
10. Goldstein L, Millis JM, Calquhoun SD. Liver transplantation for chronic hepatitis B in Asians. Transplantation 1994;9:1393-1395.
11. Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 2002;1: 327-329.
12. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-1535.
13. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35:176-181.
14. Seehofer D, Rayes N, Bechstein WO, Naumann U, Neuhaus R, Berg T, et al. Therapy of recurrent hepatitis B infection after liver tansplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases. Z Gastroenterol 2000;38:773-783.
15. Berenguer M, Prieto M, Rayon M, Bustamante M, Carrasco D, Moya A, et al. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results. Am J Gastroenterol 2001;96:526-533.
16. Shapira R, Daudi N, Klein A, Shouval D, Mor E, Tur-kaspa R, et al. Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance. Transplantation 2002;73: 820-822.
17. Mutimer D, Feraz-Neto BH, Harrison R, Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001;49:860-863.
18. Zheng SS, Wu J, Wang WL, Huang DS, Liang TB, Lu AW. Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation. Chin Med J 2002;82:445-448.
19. Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000;69: 1403-1407.
20. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002;4:137-143.
21. Neumann UP, Langrehr JM, Nauman U, Lang M, Rayes N, Steinmuller T, et al. Impact of HLA-compatibilities in patients undergoing liver transplantation for HBV-cirrhosis. Clin Transplant 2002;16:122-129.
22. Ben-Ari Z, Ashur Y, Daudi N, Shmilovitz-Wiess H, Brown M, Sulkes J, et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004;18:415-422.
23. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159.
24. Bramhall SR, Minford E, Gunson B, Buckels JA. Liver transplantation in the UK. World J Gastroenterol. 2001;7:602-611.
25. Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72:1381-1385.
26. Lagget M, Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2003; 4:1821-1827.
27. Cabrerizo M, Bartolome J, Carreno V. In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a deletion in the PreS1 region of the viral genome. J Viral Hepat 2002;9:265-271.
28. Bui Han SH, Martin P. Liver transplantation for hepatitis B. Hepatol Res 2004;29:193-201.
29. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24(Suppl 1):55-62.
30. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003;75(3 Suppl):S41-S44.
31. Yuan G, Duan Y, Wang F, Liang S Sr, Zhu L. Prevention and treatment of HBV reinfection following liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2002;10:14-16.
32. Alonso I, Herreros de Tejada A, Moreno JM, Rubio E, Lucena JL, De la Revilla J, et al. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. Transplant Proc 2003;35:1850-1851.
33. Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, et al. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Hepatobiliary Pancreat Dis Int. 2004;3:26-32.
34. Wang ZX, Ding GS, Fu H, Zhang JJ, Chen XS, Guo WY, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3: 345-348.
35. Han SH, Martin P, Edelstein M. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxix to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003;9:182.
36. Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003;23:89-100.
37. Beckebaum S, Malago M, Dirsch O, Cicinnati VR, Trippler M, Lampertico P, et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant 2003;17: 554-559.
38. Tillmann HL, Bock CT, Bleck JS, Rosenau J, Boker KH, Barg-Hock H, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003;9:191-196.
39. Wang ZX, Fu ZR, Ding GS, Zhang JJ, Fu H, Zhang M, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004;36:2315-2317.
40. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, et al. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003;71:367-375.
41. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 2001;8:237-347.
42. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001;7:113-117.
43. Haberal M, Dalgic A. New concepts in organ transplantation. Transplant Proc 2004;36:1219-1224.
44. Ying C, Clercq De E, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine-and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res 2000;48:117-124.
45. Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The role of mycophenolate acid on HBV replication in vitro. Chin J Organ Transplant 2003;24:310-312.
46. Gong ZJ, Meyer S, Clarysse C, Verslype C, Neyts J, Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999;6:229-236.
47. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998;13:14-20.
48. Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with "latent" chronic hepatitis B. Liver 2000;20:415-420.
49. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clin Liver Dis 2003;7:667-681.
50. Tisone G, Angelico M, Orlando G, Palmieri CP, Strati F, Di Paolo D, et al. Retrospective analysis of 30 patients who underwent liver transplantation without use of steroid. Transplant Proc 1999;31:2908-2909.
51. Joya PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, et al. Impact of anti-hepatitis B c-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002;73:1598-1602.
52. Montalti R, Nardo B, Bertelli R, Beltempo P, Puviani L, Vivarelli M, et al. Donor pool expansion in liver transplantation. Transplant Proc 2004;36:520-522.
53. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002;8:556-561.
54. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-1186.
55. Chen DZ, Han MZ, Yang ZF. The prevention and treatment for recurrence of hepatitis B following liver transplantation. Chin J Organ Transplant 2000;21:278-280.
56. Dahmen U, Li J, Dirsch O, Fiedler M, Lu M, Roggendorf M, et al. A new model of hepatitis B virus reinfection: liver transplantation in the woodchuck1. Transplantation 2002;74: 373-380.
57. Tennant BC, Gerin JL. The woodchuck model of hepatitis B virus infection. ILAR J 2001;42:89-102.
58. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K, et al. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 2004;77:965-972.
59. Yu AS, Keeffe EB. Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clin Liver Dis 2003;7:551-572.